Sign in

You're signed outSign in or to get full access.

NI

Nkarta, Inc. (NKTX)·Q1 2025 Earnings Summary

Executive Summary

  • GAAP EPS of -$0.43 beat Wall Street consensus of -$0.45 by $0.02; revenue was $0, in-line with consensus $0.00* .
  • Cash runway reiterated “into 2029,” with cash, cash equivalents and investments at $351.9M as of March 31, 2025 .
  • Clinical execution advanced: Ntrust-1 expanded to include primary membranous nephropathy; lymphodepletion regimen modified to include fludarabine + cyclophosphamide (cyclophosphamide-only remains an option for eligible patients) .
  • No earnings call transcript was posted by IR for Q1; company provided press release and 10-Q only .

What Went Well and What Went Wrong

What Went Well

  • Cash runway strengthened and reiterated into 2029; restructuring and cost containment cited as positioning NKTX to reach milestones while preserving flexibility .
  • Platform and trial updates likely enhance clinical optionality: expanded Ntrust-1 cohort (pMN) and dual lymphodepletion option could produce comparable datasets across regimens .
  • EPS modestly beat consensus (-$0.43 vs -$0.45), while interest income of $4.4M provided a partial offset to operating expenses* .
    • “Our recent restructuring and continued efforts at cost containment have positioned us well… into 2029” — CEO Paul J. Hastings .

What Went Wrong

  • Higher G&A ($12.4M) driven by $5.1M restructuring expense increased total OpEx sequentially vs Q4 2024, and widened net loss to $32.0M .
  • Revenue remains $0 as NKTX is pre-commercial; operating loss mirrored OpEx (no offsetting top-line) .
  • Continued dependence on clinical execution timelines (initial Ntrust-1/Ntrust-2 updates 2H 2025) underscores binary risk; management’s forward-looking statements highlight enrollment and manufacturing complexity risks .

Financial Results

MetricQ3 2024Q4 2024Q1 2025
Revenue ($USD Millions)$0.00 $0.00 $0.00
Net Loss ($USD Millions)$28.34 $25.94 $31.98
EPS ($USD)-$0.39 -$0.35 -$0.43
R&D Expense ($USD Millions)$25.25 $23.13 $24.17
G&A Expense ($USD Millions)$8.54 $7.80 $12.39
Interest Income ($USD Millions)$5.45 $4.89 $4.38
Total Operating Expenses ($USD Millions)$33.79 $30.92 $36.56

Notes:

  • Revenue is $0 across periods; the equality between “Loss from operations” and “Total operating expenses” in reported statements indicates no revenue .
  • Q1 G&A included $5.1M restructuring expense .

Segment breakdown: N/A (no commercial revenue; no reportable segments)

KPIs

KPIQ3 2024Q4 2024Q1 2025
Cash, Cash Equivalents, Restricted Cash & Investments ($USD Millions)$405.27 $380.49 $351.90
Weighted Avg. Shares (Basic & Diluted)73,563,316 73,595,401 73,916,477
Cash Runway Guidance“into late 2027” “into 2029” “into 2029”

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
Cash runwayQ3 2024 → Q4 2024Into late 2027 Into 2029 Raised
Cash runwayQ4 2024 → Q1 2025Into 2029 Into 2029 Maintained
Restructuring cash paymentsAnnounced in Q4 2024$5.5–$6.5M est. $5.1M recognized in Q1 G&A Realization/updated actual

No revenue/EPS/OpEx guidance ranges were provided beyond the restructuring detail and runway.

Earnings Call Themes & Trends

TopicPrevious Mentions (Q3 2024)Previous Mentions (Q4 2024)Current Period (Q1 2025)Trend
Lymphodepletion strategySingle-agent cyclophosphamide across trials Harmonized dosing; cyclophosphamide-only Added fludarabine + cyclophosphamide option; cyclophosphamide-only remains for eligible patients Broadening regimen to optimize outcomes
Indication scopeNtrust-2 to initiate for SSc, IIM, AAV; SLE IST ongoing First patient dosed in Ntrust-1; SLE IST dosed Ntrust-1 expanded to include pMN; MG IST opened to enrollment Expansion of autoimmune programs
NHL programDecision to forgo NHL; focus on autoimmune Continued autoimmune focus; restructure to prioritize NKX019 Autoimmune focus reiterated Completed shift
Cash runwayInto late 2027 Extended into 2029 Maintained into 2029 Strengthened then stable
Organization/costsN/A34% workforce reduction; exec team reduced >50% G&A includes $5.1M restructuring in March Cost actions realized

Management Commentary

  • “Our recent restructuring and continued efforts at cost containment have positioned us well to achieve our clinical milestones while ensuring we have cash to support our critical operations into 2029.” — CEO Paul J. Hastings .
  • “We remain confident that the potential safety and accessibility advantages of NKX019 will allow it to occupy an important place in the future treatment of autoimmune disease.” — CEO Paul J. Hastings .
  • Rationale for dual lymphodepletion: “Similar trials have established this combination… value in producing a comparable dataset while still continuing our cyclophosphamide-only regimen for eligible patients.” — CEO Paul J. Hastings .

Q&A Highlights

  • No Q1 2025 earnings call transcript available via IR; Q1 materials consist of the press release and Form 10-Q .
  • Guidance clarifications were embedded in prepared remarks (runway into 2029) and financial tables .
  • Tone: Emphasis on clinical execution and cost discipline; cautious forward-looking framing noting enrollment/manufacturing complexities .

Estimates Context

MetricPeriodConsensus*ActualSurprise
Primary EPS Consensus Mean ($)Q1 2025-$0.45*-$0.43 +$0.02 (Beat)*
Revenue Consensus Mean ($USD Millions)Q1 2025$0.00*$0.00 In-line*
Primary EPS – # of EstimatesQ1 20253*——*
Revenue – # of EstimatesQ1 20255*——*

Values retrieved from S&P Global.
Interpretation: EPS beat was modest and driven by interest income and timing/level of OpEx; revenue remains $0 given pre-commercial status .

Key Takeaways for Investors

  • Runway into 2029 provides capital flexibility and reduces near-term financing overhang; restructuring costs were recognized ($5.1M in Q1 G&A), with benefits contributing to runway extension .
  • Clinical catalysts in 2H 2025 (initial Ntrust-1/Ntrust-2 data) are the principal stock drivers; indication expansion (pMN) and lymphodepletion modification broaden potential applicability .
  • Focus fully pivoted to autoimmune; NHL no longer a near-term resource draw, aligning spend with higher-probability value inflections .
  • Earnings quality: modest EPS beat vs consensus; top-line remains $0, so OpEx and interest income drive quarterly variability* .
  • Watch operating expense trajectory post-restructuring—Q1 G&A elevated; expect normalization as one-time expenses fade .
  • Track enrollment velocity and safety across dual lymphodepletion regimens; comparative datasets may inform future protocol optimization and regulatory strategy .
  • Near-term trading implications: sentiment likely tied to clinical update timing and any interim disclosures; cash runway limits dilution risk, which can support the setup into data.

Non-GAAP note: Company did not present non-GAAP metrics; analysis relies on GAAP net loss and per-share results .